Aspen announces R500 million investment at 4th SAIC

Johannesburg, South Africa – Aspen Pharmacare, a global specialty and branded pharmaceutical company and Africa’s largest pharmaceutical company, has announced a further investment of some R500 million to its flagship pharmaceutical manufacturing site in Gqeberha.

 

The announcement comes in the wake of more than R8 billion which Aspen has already invested in this world class manufacturing site in the Eastern Cape. Implementation of the project commenced in November 2021 and the investment will provide additional capacity for fill and finish of a range of sterile products including vaccines.

Addressing guests at the South Africa Investment Conference hosted by President Cyril Ramaphosa, Stavros Nicolaou, Aspen Group Senior Executive Strategic Trade said, “Aspen remains committed to South Africa – this is where our roots are, so Gqeberha is a natural base from which to expand our manufacturing capacity for the African continent. This additional investment in capacity expansion will increase output of our 2R vaccine vials from 60 million to 150 million per annum and it will assist Africa in addressing the unequal distribution of vaccines and provide enhanced capacity for pandemic preparedness.”

As a strong advocate of local partnerships, Aspen has engaged engineering consultants and contractors from Gqerberha and Johannesburg for the project which is expected to complete in March 2023. Aspen’s highly specialised sterile pharmaceutical manufacturing facilities at the site provide employment and skills development opportunities to nearly 500 employees.

 

我们的使命

更多详情

致力于提高患者的生命健康和质量

我们的愿景

更多详情

作为一个负责任的企业公民,在全球提高优质和患者可及的药物,传递我们的价值。

我们的价值观

更多详情

我们的价值观是爱施健存立和发展的基石。集团上下以此为指引,为实现集团目标而共同奋斗。

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.